Maxim Group Begins Coverage on TuHURA Biosciences (NASDAQ:HURA)

Analysts at Maxim Group assumed coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $15.00 price target on the stock. Maxim Group’s price target indicates a potential upside of 184.63% from the stock’s previous close.

TuHURA Biosciences Trading Up 5.8 %

Shares of HURA opened at $5.27 on Tuesday. TuHURA Biosciences has a twelve month low of $2.84 and a twelve month high of $23.73.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.